163 related articles for article (PubMed ID: 35047396)
1. Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas.
Liao Z; Zhang C; Yang T; Liu H; Yang S; Li T; Xing R; Teng S; Yang Y; Zhao J; Zhao G; Bai X; Zhu L; Yang J
Front Oncol; 2021; 11():778774. PubMed ID: 35047396
[TBL] [Abstract][Full Text] [Related]
2. Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV.
Xing P; Zhang J; Yan Z; Zhao G; Li X; Wang G; Yang Y; Zhao J; Xing R; Teng S; Ma Y; Liao Z; Ren Z; Zhang C; Han X; Zhang W; Chen K; Wang P; Yang J
Oncotarget; 2017 May; 8(22):36716-36727. PubMed ID: 27888623
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of endostar® combined with chemotherapy in patients with advanced soft tissue sarcomas.
Zhang LP; Liao XY; Xu YM; Yan LJ; Yan GF; Wang XX; Duan YZ; Sun JG
Asian Pac J Cancer Prev; 2013; 14(7):4255-9. PubMed ID: 23991986
[TBL] [Abstract][Full Text] [Related]
4. Rh-endostatin Concomitant with Chemotherapy Versus Single Agent Chemotherapy for Treating Soft Tissue and Bone Sarcomas: A Systematic Review and Meta-Analysis.
Ma Z; Guo L; Cui X; Liu H; Liu L
J Pharm Pharm Sci; 2018; 21(1):386-397. PubMed ID: 30352660
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the combination of endostar with chemotherapy on stage IVb and recurrent metastatic cervical cancer.
Guo F; Chen C; Liang Y; Ma S; Zou W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 45(12):1412-1418. PubMed ID: 33472996
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
9. [Treatment and prognosis of stage IV alveolar soft part sarcoma].
Zhao J; Yang Y
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):932-6. PubMed ID: 23336381
[TBL] [Abstract][Full Text] [Related]
10. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
11. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
[TBL] [Abstract][Full Text] [Related]
12. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and adverse reactions of IMRT combined with Endostar versus IMRT combined with chemotherapy for locally advanced nasopharyngeal carcinoma: a retrospective study.
Chen W; Wang F; Yang Z; Zhang T; Shen M; Wang R; Kang M
Ann Palliat Med; 2021 Nov; 10(11):11891-11900. PubMed ID: 34872313
[TBL] [Abstract][Full Text] [Related]
16. Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer.
Yang H; Sui Y; Guo X; Tan X; Li Y; Wang M
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1148-S1151. PubMed ID: 30539861
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
19. Clinical observation of local intervention combined with camrelizumab and apatinib in the treatment of metastatic soft-tissue sarcoma.
Li Y; Li HL; Hu HT; Shao SS; Chen CS; Guo CY; Zhao Y; Yao QJ
J Cancer Res Ther; 2021 Dec; 17(7):1718-1724. PubMed ID: 35381744
[TBL] [Abstract][Full Text] [Related]
20. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]